Previous 10 |
home / stock / oxbdf / oxbdf news
The purpose of this article is to take an in-depth look at Axovant Sciences' ( AXON ) Parkinson's gene therapy which was briefly touched on in my previous article . Parkinson's disease Parkinson’s is a chronic, progressive and debilitating neurodegenerative resulting in the loss o...
News, Short Squeeze, Breakout and More Instantly...
EXPRESS INC. DL-01 (02Z0:DU) is expected to report $-8.99 for Q4 2024 Oxford Biomedica (OXBDF) is expected to report for Q4 2023 Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q4 2024 Express (02Z0:MU) is expected to report $-8.99 for Q4 2024 Express Inc. - Ord...
Oxford Biomedica (OXBDF) is expected to report for Q4 2023
LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emer...